Centric Wealth Management Purchases 15,021 Shares of Johnson & Johnson $JNJ

Centric Wealth Management grew its position in Johnson & Johnson (NYSE:JNJ) by 436.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,461 shares of the company’s stock after acquiring an additional 15,021 shares during the quarter. Centric Wealth Management’s holdings in Johnson & Johnson were worth $3,062,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $47,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $49,000. Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $50,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $52,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. Leerink Partnrs downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Wall Street Zen cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Finally, Citigroup boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $177.10 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The stock has a market capitalization of $426.52 billion, a price-to-earnings ratio of 18.94, a P/E/G ratio of 2.23 and a beta of 0.41. The stock has a fifty day simple moving average of $165.99 and a two-hundred day simple moving average of $160.01. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the prior year, the business earned $2.82 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.